BridgeBio Pharma, Inc. Research and Development Expense
BridgeBio Pharma, Inc. (BBIO) reported Research and Development Expense of $149.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- BridgeBio Pharma, Inc. research and development expense for the quarter ending 2026-06-30 was $149.45M, a 34.36% increase year-over-year.
- BridgeBio Pharma, Inc. research and development expense for the quarter ending 2026-03-31 was $126.64M, a 13.65% increase year-over-year.
- BridgeBio Pharma, Inc. research and development expense for the quarter ending 2025-12-31 was $116.42M, a 10.69% decline year-over-year.
- BridgeBio Pharma, Inc. research and development expense for the quarter ending 2025-09-30 was $112.87M, a 6.29% decline year-over-year.
- BridgeBio Pharma, Inc. research and development expense for fiscal 2025 was $451.95M, a 10.76% decline from fiscal 2024.
- BridgeBio Pharma, Inc. research and development expense for fiscal 2024 was $506.46M, a 11.14% increase from fiscal 2023.
- BridgeBio Pharma, Inc. research and development expense for fiscal 2023 was $455.71M, a 14.08% increase from fiscal 2022.
- BridgeBio Pharma, Inc. research and development expense for fiscal 2022 was $399.46M, a 11.43% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $149.45M 10-Q · filed 2026-08-10 | $276.08M 10-Q · filed 2026-08-10 | $392.50M derived: sum of 3 quarters · filed 2026-08-10 | $505.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $126.64M 10-Q · filed 2026-05-07 | $243.05M derived: sum of 2 quarters · filed 2026-05-07 | $355.93M derived: sum of 3 quarters · filed 2026-05-07 | $467.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $116.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $229.29M derived: sum of 2 quarters · filed 2026-02-24 | $340.52M derived: sum of 3 quarters · filed 2026-08-10 | $451.95M 10-K · filed 2026-02-24 |
| 2025-09-30 | $112.87M 10-Q · filed 2025-10-29 | $224.10M derived: sum of 2 quarters · filed 2026-08-10 | $335.54M 10-Q · filed 2025-10-29 | $465.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $111.23M 10-Q · filed 2026-08-10 | $222.66M 10-Q · filed 2026-08-10 | $353.01M derived: sum of 3 quarters · filed 2026-08-10 | $473.46M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $111.43M 10-Q · filed 2026-05-07 | $241.78M derived: sum of 2 quarters · filed 2026-05-07 | $362.23M derived: sum of 3 quarters · filed 2026-05-07 | $476.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $130.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $250.79M derived: sum of 2 quarters · filed 2026-02-24 | $365.49M derived: sum of 3 quarters · filed 2026-02-24 | $506.46M 10-K · filed 2026-02-24 |
| 2024-09-30 | $120.44M 10-Q · filed 2025-10-29 | $235.14M derived: sum of 2 quarters · filed 2025-10-29 | $376.11M 10-Q · filed 2025-10-29 | $506.34M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $114.69M 10-Q · filed 2025-08-05 | $255.67M 10-Q · filed 2025-08-05 | $385.89M derived: sum of 3 quarters · filed 2026-02-24 | $511.03M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $140.97M 10-Q · filed 2025-04-29 | $271.20M derived: sum of 2 quarters · filed 2026-02-24 | $396.33M derived: sum of 3 quarters · filed 2026-02-24 | $503.82M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $130.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $255.36M derived: sum of 2 quarters · filed 2026-02-24 | $362.85M derived: sum of 3 quarters · filed 2026-02-24 | $455.71M 10-K · filed 2026-02-24 |
| 2023-09-30 | $125.14M 10-Q · filed 2024-11-12 | $232.62M derived: sum of 2 quarters · filed 2024-11-12 | $325.49M 10-Q · filed 2024-11-12 | $416.39M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $107.49M 10-Q · filed 2024-08-01 | $200.35M 10-Q · filed 2024-08-01 | $291.25M derived: sum of 3 quarters · filed 2025-02-20 | $383.76M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $92.86M 10-Q · filed 2024-05-02 | $183.76M derived: sum of 2 quarters · filed 2025-02-20 | $276.27M derived: sum of 3 quarters · filed 2025-02-20 | $384.67M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $90.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $183.41M derived: sum of 2 quarters · filed 2025-02-20 | $291.81M derived: sum of 3 quarters · filed 2025-02-20 | $399.46M 10-K · filed 2025-02-20 |
| 2022-09-30 | $92.51M 10-Q · filed 2023-11-02 | $200.91M derived: sum of 2 quarters · filed 2023-11-02 | $308.56M 10-Q · filed 2023-11-02 | $430.76M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $108.40M 10-Q · filed 2023-08-03 | $216.05M 10-Q · filed 2023-08-03 | $338.25M derived: sum of 3 quarters · filed 2024-02-22 | $442.55M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $107.65M 10-Q · filed 2023-05-04 | $229.85M derived: sum of 2 quarters · filed 2024-02-22 | $334.15M derived: sum of 3 quarters · filed 2024-02-22 | $436.11M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $122.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $226.50M derived: sum of 2 quarters · filed 2024-02-22 | $328.46M derived: sum of 3 quarters · filed 2024-02-22 | $451.02M 10-K · filed 2024-02-22 |
| 2021-09-30 | $104.31M 10-Q · filed 2022-11-03 | $206.26M derived: sum of 2 quarters · filed 2022-11-03 | $328.82M 10-Q · filed 2022-11-03 | $419.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $101.96M 10-Q · filed 2022-08-04 | $224.52M 10-Q · filed 2022-08-04 | $314.69M derived: sum of 3 quarters · filed 2023-02-23 | $406.74M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $122.56M 10-Q · filed 2022-05-05 | $212.73M derived: sum of 2 quarters · filed 2023-02-23 | $304.78M derived: sum of 3 quarters · filed 2023-02-23 | $391.38M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $90.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $182.22M derived: sum of 2 quarters · filed 2023-02-23 | $268.82M derived: sum of 3 quarters · filed 2023-02-23 | $337.05M 10-K · filed 2023-02-23 |
| 2020-09-30 | $92.05M 10-Q · filed 2021-11-04 | $178.65M derived: sum of 2 quarters · filed 2021-11-04 | $246.87M 10-Q · filed 2021-11-04 | $304.36M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $86.60M 10-Q · filed 2021-08-05 | $154.82M 10-Q · filed 2021-08-05 | $212.31M derived: sum of 3 quarters · filed 2022-02-25 | $267.59M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $68.22M 10-Q · filed 2021-05-06 | $125.71M derived: sum of 2 quarters · filed 2022-02-25 | $180.99M derived: sum of 3 quarters · filed 2022-02-25 | $233.32M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $57.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $112.76M derived: sum of 2 quarters · filed 2022-02-25 | $165.09M derived: sum of 3 quarters · filed 2022-02-25 | $209.95M 10-K · filed 2022-02-25 |
| 2019-09-30 | $55.28M 10-Q · filed 2020-11-05 | $107.61M derived: sum of 2 quarters · filed 2020-11-05 | $152.46M 10-Q · filed 2020-11-05 | $203.66M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $52.33M 10-Q · filed 2020-08-11 | $97.18M 10-Q · filed 2020-08-11 | $148.39M derived: sum of 3 quarters · filed 2021-02-25 | $179.53M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $44.85M 10-Q · filed 2020-05-14 | $96.06M derived: sum of 2 quarters · filed 2021-02-25 | $127.20M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | $51.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $82.35M derived: sum of 2 quarters · filed 2021-02-25 | $140.07M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $31.15M 10-Q · filed 2019-11-08 | $88.87M 10-Q · filed 2019-11-08 | ||
| 2017-12-31 | $30.56M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |